We are live on ! Find out more
BCM

Biomark Capital Management Portfolio holdings

AUM $8.9M
1-Year Est. Return 97.06%
This Fund
S&P 500
This Quarter Est. Return
-15.92%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$75.6M
AUM Growth
-$2.37M
Cap. Flow
-$1.15M
Cap. Flow %
-1.52%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
MBVX
MABVAX THERAPEUTICS HLDGS INC
MBVX
+$134K

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$1.16M

Sector Composition

Rank Sector Weight
1 Healthcare 13.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
1
DELISTED
Juno Therapeutics, Inc.
JUNO
$65.1M 86.12%
2,168,601
-37,325
-2% -$1.16M
ADMA icon
2
ADMA Biologics
ADMA
$1.96B
$10.4M 13.73%
1,433,304
– –
MBVX
3
DELISTED
MABVAX THERAPEUTICS HLDGS INC
MBVX
$113K 0.15%
+8,903
New +$134K

Similar funds

OBP
Old Bellows Partners New York $9.01M AUM 83.84% 1-Year Est. Return
HC
Highstar Capital New York $8.59M AUM 3.82% 1-Year Est. Return
SBA
Seven Bridges Advisors New York $9.75M AUM 16.73% 1-Year Est. Return
CIG
Candlewood Investment Group Rye, New York $10.1M AUM 30% 1-Year Est. Return
LRM
Lime Rock Management Westport, Connecticut $7.54M AUM 22.09% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
GA
Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return
CCM
Catalus Capital Management Greenwich, Connecticut $6.09M AUM 3.76% 1-Year Est. Return

Biomark Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Biomark Capital Management held 4 positions worth $75.6M, down 3% from $77.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Biomark Capital Management's Q3 2016 filing shows 1 new, 1 reduced and 1 closed positions. Its largest new stake was MABVAX THERAPEUTICS HLDGS INC: 8,903 shares worth $113K. The largest sale was Juno Therapeutics, Inc., an estimated $1.16M.

By sector, the portfolio is most concentrated in Healthcare at 14% of assets, up from 12% a quarter earlier.

  • Biomark Capital Management's largest Q3 2016 buy was MABVAX THERAPEUTICS HLDGS INC: 8,903 shares worth $113K.
  • Biomark Capital Management's biggest Q3 2016 reduction was Juno Therapeutics, Inc., cutting an estimated $1.16M.
  • Biomark Capital Management's ten largest holdings make up 100% of its $75.6M portfolio in Q3 2016.
  • Biomark Capital Management opened 1 new position and closed 1 in Q3 2016.
  • Biomark Capital Management's portfolio value fell 3% quarter-over-quarter to $75.6M.

Based on Biomark Capital Management's 13F filing for Q3 2016, filed 9 Nov 2016.